Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention in Postmenopausal Women

Mayo Clinic Proceedings

Volumn 91, Issue 1, 2016, Pages 71-80

  Bardia, Aditya ^a   Keenan, Tanya E ^a   Ebbert, Jon O ^b   Lazovich, Deann ^c   Wang, Alice H ^b   Vierkant, Robert A ^b   Olson, Janet E ^b   Vachon, Celine M ^b   Limburg, Paul J ^b   Anderson, Kristin E ^c   Cerhan, James R ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; DISEASE ASSOCIATION; DRUG USE; FAMILY HISTORY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LOW RISK POPULATION; MEDICAL HISTORY; MENARCHE; PARITY; PERSONALIZED MEDICINE; POSTMENOPAUSE; PROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; AGE; BREAST NEOPLASMS; CHEMOPROPHYLAXIS; COHORT ANALYSIS; IOWA; MIDDLE AGED; OUTCOME ASSESSMENT; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REPRODUCTIVE HISTORY; RISK ASSESSMENT; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

AGE FACTORS; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BREAST NEOPLASMS; CHEMOPREVENTION; COHORT STUDIES; FEMALE; HUMANS; IOWA; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; REPRODUCTIVE HISTORY; RISK ASSESSMENT; RISK FACTORS;

EID: 84952862466     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2015.10.018     Document Type: Article

References (61)

1. B.K. Edwards, A.M. Noone, A.B. Mariotto, and et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer Cancer 120 9 2014 1290 1314
2. National Cancer Institute. SEER Stat Fact Sheets: Breast Cancer Statistics. SEER website. http://seer.cancer.gov/statfacts/html/breast.html. Accessed August 10, 2015.
3. A. Rostom, C. Dubé, G. Lewin, et al. US Preventive Services Task Force Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U. S. Preventive Services Task Force Ann Intern Med 146 5 2007 376 389
4. C. Bosetti, V. Rosato, S. Gallus, J. Cuzick, and C. La Vecchia Aspirin and cancer risk: a quantitative review to 2011 Ann Oncol 23 6 2012 1403 1415
5. R.E. Harris, J. Beebe-Donk, H. Doss, and D. Burr Doss Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review) Oncol Rep 13 4 2005 559 583
6. J. Cuzick, F. Otto, J.A. Baron, and et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement Lancet Oncol 10 5 2009 501 507
7. M.J. Thun, E.J. Jacobs, and C. Patrono The role of aspirin in cancer prevention Nat Rev Clin Oncol 9 5 2012 259 267
8. P.M. Rothwell, J.F. Price, F.G. Fowkes, and et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials Lancet 379 9826 2012 1602 1612
9. V. Hial, Z. Horakova, F.E. Shaff, and M.A. Beaven Alteration of tumor growth by aspirin and indomethacin: studies with two transplantable tumors in mouse Eur J Pharmacol 37 2 1976 367 376
10. A. Bennett, and B.P. Curwain Effects of aspirin-like drugs on canine gastric mucosal blood flow and acid secretion Br J Pharmacol 60 4 1977 499 504
11. R.A. Karmali, S. Welt, H.T. Thaler, and F. Lefevre Prostaglandins in breast cancer: relationship to disease stage and hormone status Br J Cancer 48 5 1983 689 696
12. J. Watson, and S.Y. Chuah Prostaglandins, steroids and human mammary cancer Eur J Cancer Clin Oncol 21 9 1985 1051 1055
13. A.J. Dannenberg, S.M. Lippman, J.R. Mann, K. Subbaramaiah, and R.N. DuBois Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention J Clin Oncol 23 2 2005 254 266
14. B. Su, E.S. Diaz-Cruz, S. Landini, and R.W. Brueggemeier Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition Steroids 73 1 2008 104 111
15. D.M. Schreinemachers, and R.B. Everson Aspirin use and lung, colon, and breast cancer incidence in a prospective study Epidemiology 5 2 1994 138 146
16. R.E. Harris, K. Namboodiri, S.D. Stellman, and E.L. Wynder Breast cancer and NSAID use: heterogeneity of effect in a case-control study Prev Med 24 2 1995 119 120
17. R.E. Harris, K.K. Namboodiri, and W.B. Farrar Nonsteroidal antiinflammatory drugs and breast cancer Epidemiology 7 2 1996 203 205
18. P.F. Coogan, S.R. Rao, L. Rosenberg, and et al. The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer Prev Med 29 2 1999 72 76
19. C.R. Sharpe, J.P. Collet, M. McNutt, E. Belzile, J.F. Boivin, and J.A. Hanley Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage Br J Cancer 83 1 2000 112 120
20. M.B. Terry, M.D. Gammon, F.F. Zhang, and et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk JAMA 291 20 2004 2433 2440
21. S.F. Marshall, L. Bernstein, H. Anton-Culver, and et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status J Natl Cancer Inst 97 11 2005 805 812
22. E. Rahme, J. Ghosn, K. Dasgupta, R. Rajan, and M. Hudson Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer BMC Cancer 5 2005 159
23. Y. Zhang, P.F. Coogan, J.R. Palmer, B.L. Strom, and L. Rosenberg Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the Case-Control Surveillance Study revisited Am J Epidemiol 162 2 2005 165 170
24. V.A. Kirsh, N. Kreiger, M. Cotterchio, M. Sloan, and B. Theis Nonsteroidal antiinflammatory drug use and breast cancer risk: subgroup findings Am J Epidemiol 166 6 2007 709 716
25. A. Ready, C.M. Velicer, A. McTiernan, and E. White NSAID use and breast cancer risk in the VITAL cohort Breast Cancer Res Treat 109 3 2008 533 543
26. R.E. Harris, R.T. Chlebowski, R.D. Jackson, and et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative Cancer Res 63 18 2003 6096 6101
27. K.M. Egan, M.J. Stampfer, E. Giovannucci, B.A. Rosner, and G.A. Colditz Prospective study of regular aspirin use and the risk of breast cancer J Natl Cancer Inst 88 14 1996 988 993
28. E.J. Jacobs, M.J. Thun, C.J. Connell, and et al. Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort Cancer Epidemiol Biomarkers Prev 14 1 2005 261 264
29. J.K. Gill, G. Maskarinec, L.R. Wilkens, M.C. Pike, B.E. Henderson, and L.N. Kolonel Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort Am J Epidemiol 166 10 2007 1150 1158
30. G.L. Gierach, J.V. Lacey Jr., A. Schatzkin, and et al. Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study Breast Cancer Res 10 2 2008 R38
31. T.W. Johnson, K.E. Anderson, D. Lazovich, and A.R. Folsom Association of aspirin and other nonsteroidal anti-inflammatory drug use with breast cancer Cancer Epidemiol Biomarkers Prev 11 12 2002 1586 1591
32. G.N. Hortobagyi, and P.H. Brown Two good choices to prevent breast cancer: great taste, less filling Cancer Prev Res (Phila) 3 6 2010 681 685
33. A.R. Folsom, S.A. Kaye, R.J. Prineas, J.D. Potter, S.M. Gapstur, and R.B. Wallace Increased incidence of carcinoma of the breast associated with abdominal adiposity in postmenopausal women Am J Epidemiol 131 5 1990 794 803
34. K.M. Bisgard, A.R. Folsom, C.P. Hong, and T.A. Sellers Mortality and cancer rates in nonrespondents to a prospective study of older women: 5-year follow-up Am J Epidemiol 139 10 1994 990 1000
35. X.R. Yang, J. Chang-Claude, E.L. Goode, and et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies J Natl Cancer Inst 103 3 2011 250 263
36. M.H. Gail, L.A. Brinton, D.P. Byar, and et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually J Natl Cancer Inst 81 24 1989 1879 1886
37. Ries LAG, Melbert D, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2005. SEER website. http://seer.cancer.gov/csr/1975-2005/. Published 2008. Accessed August 10, 2015.
38. A. Bardia, J.E. Olson, C.M. Vachon, and et al. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study Breast Cancer Res Treat 126 1 2011 149 155
39. E.L. Korn, B.I. Graubard, and D. Midthune Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale Am J Epidemiol 145 1 1997 72 80
40. D. Suissa, P. Brassard, B. Smiechowski, and S. Suissa Number needed to treat is incorrect without proper time-related considerations J Clin Epidemiol 65 1 2012 42 46
41. X. Zhang, S.A. Smith-Warner, L.C. Collins, B. Rosner, W.C. Willett, and S.E. Hankinson Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence J Clin Oncol 30 28 2012 3468 3477
42. M.J. Langman, K.K. Cheng, E.A. Gilman, and R.J. Lancashire Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database BMJ 320 7250 2000 1642 1646
43. T. Luo, H.M. Yan, P. He, Y. Luo, Y.F. Yang, and H. Zheng Aspirin use and breast cancer risk: a meta-analysis Breast Cancer Res Treat 131 2 2012 581 587
44. N.R. Cook, I.M. Lee, J.M. Gaziano, and et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study; a randomized controlled trial JAMA 294 1 2005 47 55
45. M.D. Holmes, W.Y. Chen, L. Li, E. Hertzmark, D. Spiegelman, and S.E. Hankinson Aspirin intake and survival after breast cancer J Clin Oncol 28 9 2010 1467 1472
46. C.K. Blair, C. Sweeney, K.E. Anderson, and A.R. Folsom NSAID use and survival after breast cancer diagnosis in post-menopausal women Breast Cancer Res Treat 101 2 2007 191 197
47. S. Zhong, X. Zhang, L. Chen, T. Ma, J. Tang, and J. Zhao Association between aspirin use and mortality in breast cancer patients: a meta-analysis of observational studies Breast Cancer Res Treat 150 1 2015 199 207
48. G.A. Colditz, B.A. Rosner, W.Y. Chen, M.D. Holmes, and S.E. Hankinson Risk factors for breast cancer according to estrogen and progesterone receptor status J Natl Cancer Inst 96 3 2004 218 228
49. L. Gallicchio, M.A. McSorley, C.J. Newschaffer, and et al. Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease Cancer 106 7 2006 1443 1452
50. X. Liao, P. Lochhead, R. Nishihara, and et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival N Engl J Med 367 17 2012 1596 1606
51. B.H. Choi, G. Chakraborty, K. Baek, and H.S. Yoon Aspirin-induced Bcl-2 translocation and its phosphorylation in the nucleus trigger apoptosis in breast cancer cells Exp Mol Med 45 2013 e47
52. L. Huang, C.C. Wong, G.G. Mackenzie, and et al. Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress BMC Cancer 14 2014 141
53. A. González-Pérez, L.A. García Rodríguez, and R. López-Ridaura Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis BMC Cancer 3 2003 28
54. Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers N Engl J Med 330 15 1994 1029 1035
55. E. Lonn, J. Bosch, S. Yusuf, et al. HOPE and HOPE-TOO Trial Investigators Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial JAMA 293 11 2005 1338 1347
56. S.M. Lippman, E.A. Klein, P.J. Goodman, and et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) JAMA 301 1 2009 39 51
57. J.M. Gaziano, R.J. Glynn, W.G. Christen, and et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial JAMA 301 1 2009 52 62
58. A.M. Brewster, S.L. Patterson, M.R. Forman, and et al. Conference Report: Eighth Annual AACR International Conference on Frontiers in Cancer Prevention Research Cancer Prev Res (Phila) 3 8 2010 1044 1048
59. J. Cuzick, A. DeCensi, B. Arun, and et al. Preventive therapy for breast cancer: a consensus statement Lancet Oncol 12 5 2011 496 503
60. B. Arun, B.K. Dunn, L.G. Ford, and A. Ryan Breast cancer prevention trials: large and small trials Semin Oncol 37 4 2010 367 383
61. I.P. Uray, and P.H. Brown Chemoprevention of hormone receptor-negative breast cancer: new approaches needed Recent Results Cancer Res 188 2011 147 162